EYPT Q2 2020 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-42.8% YoY

Gross Profit

$4M87.8% margin

Operating Income

-$11M-270.5% margin

Net Income

-$13M-314.2% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

-45.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$735,000

Balance Sheet

Total Assets

$70M

Total Liabilities

$65M

Stockholders' Equity

$4M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$7M	-42.8%
Gross Profit	$4M	$7M	-44.3%
Operating Income	-$11M	-$10M	-9.7%
Net Income	-$13M	-$11M	-12.6%

Revenue Segments

Product

$4M50%

Y U T I Q Product

$3M39%

D E X Y C U Product

$827,00011%